About Vacuolar fusion protein CCZ1 homolog B
Vacuolar fusion protein CCZ1 homolog B (CCZ1B) is a protein
from Homo sapiens identified by UniProt accession
P86790, 482 residues long.
MolForge cross-references it against 0 known binders and
21 disease associations.
Target properties
| Protein name | Vacuolar fusion protein CCZ1 homolog B |
| UniProt accession | P86790 |
| Gene | CCZ1B |
| Organism | Homo sapiens |
| Length | 482 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (21)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.32
- Myopia · score 0.23
- age at onset · score 0.23
- appendicular lean mass · score 0.23
- reticulocyte measurement · score 0.22
- mitochondrial heteroplasmy measurement · score 0.19
- refractive error · score 0.19
- reticulocyte count · score 0.11
- sex hormone-binding globulin measurement · score 0.07
- leukocyte count · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P86790-F1 | alphafold | PREDICTED | 88.10 | — |
Amino-acid sequence (482 residues)
MAAAAAGAGS GPWAAQEKQF PPALLSFFIY NPRFGPREGQ EENKILFYHP NEVEKNEKIR NVGLCEAIVQ FTRTFSPSKP AKSLHTQKNR QFFNEPEENF WMVMVVRNPI IEKQSKDGKP VIEYQEEELL DKVYSSVLRQ CYSMYKLFNG TFLKAMEDGG VKLLKERLEK FFHRYLQTLH LQSCDLLDIF GGISFFPLDK MTYLKIQSFI NRMEESLNIV KYTAFLYNDQ LIWSGLEQDD MRILYKYLTT SLFPRHIEPE LAGRDSPIRA EMPGNLQHYG RFLTGPLNLN DPDAKCRFPK IFVNTDDTYE ELHLIVYKAM SAAVCFMIDA SVHPTLDFCR RLDSIVGPQL TVLASDICEQ FNINKRMSGS EKEPQFKFIY FNHMNLAEKS TVHMRKTPSV SLTSVHPDLM KILGDINSDF TRVDEDEEII VKAMSDYWVV GKKSDRRELY VILNQKNANL IEVNEEVKKL CATQFNNIFF LD
Explore Vacuolar fusion protein CCZ1 homolog B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets